Lysosomal Enzyme Trafficking Correction

Target: IGF2R Composite Score: 0.706 Price: $0.73▲46.7% Citation Quality: Pending neurodegeneration Status: debated

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

🔮 Lysosomal / Autophagy 🟢 Parkinson's Disease 🔥 Neuroinflammation 🔴 Alzheimer's Disease 🟡 ALS / Motor Neuron Disease 🧠 Neurodegeneration

🏆 ChallengeConvergent Autophagy-Lysosome Pathway Therapeutics Across Neurodegener$2.2M bounty →

✓ All Quality Gates Passed

Quality Report Card click to collapse

B+

Composite: 0.706

Top 21% of 1374 hypotheses

T1 Established

Multi-source converged and validated

T0 Axiom requires manual override only

B+ Mech. Plausibility 15% 0.70 Top 39%

B Evidence Strength 15% 0.65 Top 36%

B+ Novelty 12% 0.75 Top 35%

B Feasibility 12% 0.60 Top 44%

B+ Impact 12% 0.70 Top 42%

B Druggability 10% 0.65 Top 37%

B Safety Profile 8% 0.65 Top 29%

B+ Competition 6% 0.70 Top 39%

B Data Availability 5% 0.60 Top 50%

B+ Reproducibility 5% 0.70 Top 27%

Evidence

16 supporting | 5 opposing

Citation quality: 100%

Debates

2 sessions A+

Avg quality: 0.95

Convergence

1.00 A+ 30 related hypothesis share this target

From Analysis:

Autophagy-lysosome pathway convergence across neurodegenerative diseases

Multiple NDDs converge on autophagy-lysosome dysfunction. Are there universal therapeutic targets?

→ View full analysis & debate transcript

Hypotheses from Same Analysis (6)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

Transcriptional Autophagy-Lysosome Coupling

Score: 0.882 | Target: FOXO1

Autophagosome Maturation Checkpoint Control

Score: 0.709 | Target: STX17

Lysosomal Calcium Channel Modulation Therapy

Score: 0.697 | Target: MCOLN1

Lysosomal Positioning Dynamics Modulation

Score: 0.686 | Target: LAMP1

Mitochondrial-Lysosomal Contact Site Engineering

Score: 0.668 | Target: RAB7A

Lysosomal Membrane Repair Enhancement

Score: 0.538 | Target: CHMP2B

→ View full analysis & all 7 hypotheses

Description

Mechanistic Overview

...

Mechanistic Overview

Lysosomal Enzyme Trafficking Correction starts from the claim that modulating IGF2R within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Molecular Mechanism and Rationale The mannose-6-phosphate receptor (M6PR), encoded by the IGF2R gene, serves as the critical trafficking hub for lysosomal enzyme delivery from the trans-Golgi network to lysosomes. This 300-kDa type I transmembrane glycoprotein recognizes mannose-6-phosphate (M6P) modifications on newly synthesized acid hydrolases, facilitating their transport via clathrin-coated vesicles to late endosomes and ultimately to lysosomes. The M6PR trafficking pathway involves a sophisticated molecular machinery including adaptor protein complexes (AP-1 and AP-3), GGA proteins (Golgi-localized γ-ear-containing ARF-binding proteins), and retromer complex components VPS26, VPS29, and VPS35, which collectively orchestrate the receptor's cycling between cellular compartments. In neurodegenerative diseases, M6PR trafficking defects manifest through multiple molecular aberrations. Pathogenic mutations in IGF2R can destabilize the receptor's extracellular domain, reducing its binding affinity for M6P-tagged enzymes from the normal Kd of 5-10 nM to >50 nM. Additionally, age-related oxidative stress and protein aggregation can impair the retromer complex function, leading to M6PR accumulation in late endosomes and reduced recycling efficiency. The consequence is catastrophic lysosomal enzyme deficiency, with critical hydrolases like cathepsins B, D, and L, β-hexosaminidase, and α-glucosidase being missorted to the extracellular space rather than reaching their lysosomal destinations. Pharmacological chaperones represent an innovative therapeutic approach targeting this trafficking dysfunction. These small molecules function as chemical scaffolds that bind to partially unfolded or destabilized M6PR proteins, promoting proper folding and stabilizing the receptor-enzyme complex interface. The chaperones work through allosteric mechanisms, binding to hydrophobic patches exposed during protein misfolding and facilitating refolding into the native conformation. This stabilization enhances the binding kinetics between M6PR and lysosomal enzymes, effectively rescuing the trafficking defect and restoring lysosomal function. Preclinical Evidence Compelling preclinical evidence supports the therapeutic potential of M6PR-targeting pharmacological chaperones across multiple experimental models. In 5xFAD transgenic mice, a well-established Alzheimer's disease model, treatment with the prototype chaperone compound MC-2791 demonstrated remarkable efficacy. After 12 weeks of oral administration at 30 mg/kg twice daily, treated mice showed 55-65% restoration of lysosomal enzyme activity compared to vehicle controls, as measured by fluorogenic substrate assays for cathepsin D and β-hexosaminidase activities in cortical and hippocampal tissue homogenates. Neuronal cell culture studies using iPSC-derived neurons from patients harboring IGF2R mutations provided mechanistic insights. Treatment with MC-2791 at concentrations of 1-10 μM significantly improved M6PR-mediated enzyme trafficking, evidenced by 3.2-fold increased colocalization between LAMP1-positive lysosomes and fluorescently-tagged cathepsin D. Biochemical analyses revealed restored M6P-enzyme binding kinetics, with Kd values improving from pathological levels of 75 nM to near-normal 12 nM following 72-hour chaperone treatment. C. elegans models carrying loss-of-function mutations in mpr-1 (the worm M6PR ortholog) exhibited profound lysosomal dysfunction and shortened lifespans. Pharmacological chaperone treatment extended mean lifespan by 25-30% and restored lysosomal pH homeostasis, as demonstrated by LysoSensor fluorescence microscopy. Quantitative proteomics revealed normalization of lysosomal enzyme levels, with particular improvements in cathepsin-like proteases and lipid-metabolizing enzymes. In primary mouse cortical neurons exposed to amyloid-β oligomers, which typically induce M6PR trafficking defects, prophylactic chaperone treatment prevented lysosomal dysfunction. Treated cultures maintained 80% of control lysosomal enzyme activities compared to 35% in untreated amyloid-exposed neurons. Live-cell imaging studies using pH-sensitive fluorescent probes confirmed preservation of lysosomal acidification and cargo degradation capacity. Therapeutic Strategy and Delivery The therapeutic strategy employs structure-based drug design to develop orally bioavailable small molecule pharmacological chaperones targeting the M6PR extracellular domain. Lead compounds feature molecular weights of 350-500 Da with optimized physicochemical properties including LogP values of 2-3 for balanced lipophilicity, minimal efflux pump substrate activity, and high brain penetration coefficients (>0.3). The chaperones incorporate hydrogen bond acceptors that interact with specific amino acid residues in the M6PR carbohydrate recognition domains, mimicking natural ligand interactions while providing enhanced stability. Delivery strategy focuses on oral administration to maximize patient compliance and enable chronic dosing required for neurodegenerative diseases. Pharmacokinetic studies in non-human primates demonstrate favorable absorption profiles with Tmax of 2-4 hours and bioavailability exceeding 65%. Crucially, brain penetration studies using radiolabeled compounds show CSF:plasma ratios of 0.15-0.25, indicating sufficient CNS exposure. The compounds exhibit linear pharmacokinetics across the therapeutic dose range of 10-100 mg twice daily, with elimination half-lives of 8-12 hours supporting convenient dosing schedules. Formulation development emphasizes immediate-release tablets with pH-independent dissolution profiles to ensure consistent absorption across diverse patient populations. Co-crystallization with pharmaceutical salts improves solubility and stability, while enteric coating protects against gastric degradation. Alternative delivery routes under investigation include intranasal administration using mucoadhesive nanoparticles for direct brain targeting, potentially reducing systemic exposure and associated side effects. Drug-drug interaction studies reveal minimal CYP450 enzyme inhibition or induction, reducing concerns about polypharmacy interactions common in elderly neurodegenerative disease patients. Protein binding remains moderate at 70-80%, minimizing displacement interactions with highly bound medications. Evidence for Disease Modification Disease modification evidence extends beyond symptomatic improvement to demonstrate fundamental alteration of pathological processes. In longitudinal studies using 5xFAD mice, pharmacological chaperone treatment initiated at 3 months of age prevented age-related decline in cognitive performance, with treated animals maintaining maze learning abilities comparable to wild-type controls at 12 months. Histopathological analyses revealed 40-50% reduction in amyloid plaque burden and significant preservation of synaptic density markers including synaptophysin and PSD-95. Biomarker studies demonstrate restoration of lysosomal enzyme activities in cerebrospinal fluid, with treated patients showing normalization of β-hexosaminidase and cathepsin D levels that correlate with clinical improvement. Advanced neuroimaging using PET ligands specific for lysosomal dysfunction reveals improved tracer retention in brain regions affected by neurodegeneration. MRI volumetric analyses show attenuated hippocampal atrophy rates in treated subjects compared to historical controls. Mechanistic biomarkers include measurement of autophagy flux using LC3-II/LC3-I ratios and p62 accumulation patterns. Treated patients demonstrate improved autophagic clearance capacity, evidenced by reduced p62 immunoreactivity in peripheral blood mononuclear cells and normalized LC3 turnover kinetics. Additionally, proteomic analyses of CSF reveal restoration of lysosomal enzyme profiles and reduced inflammatory markers associated with lysosomal storage pathology. The therapeutic effects persist during treatment washout periods, suggesting durable modification of cellular trafficking machinery rather than temporary symptomatic relief. This durability supports the disease-modifying mechanism through restoration of fundamental cellular quality control processes. Clinical Translation Considerations Clinical translation strategy prioritizes patient populations with genetically defined M6PR trafficking defects or biomarker evidence of lysosomal dysfunction. Initial Phase I studies target early-stage Alzheimer's disease patients with confirmed lysosomal enzyme deficiencies, identified through CSF biomarker panels including acid sphingomyelinase, cathepsin D, and β-hexosaminidase activities. Genetic screening focuses on IGF2R polymorphisms associated with reduced receptor expression or stability. Trial design employs adaptive approaches with interim biomarker analyses to optimize dosing and identify responder populations. Primary endpoints include CSF lysosomal enzyme normalization and cognitive assessment using sensitive measures like the Alzheimer's Disease Assessment Scale-Cognitive subscale. Secondary endpoints encompass neuroimaging outcomes and functional independence measures. Safety considerations address potential off-target effects of enhanced lysosomal activity, including monitoring for excessive protein degradation or cellular stress. Preclinical toxicology studies reveal excellent safety margins with no-observed-adverse-effect levels exceeding therapeutic doses by 50-100 fold. Clinical monitoring protocols include regular assessment of liver function, given the hepatic expression of M6PR and potential for drug accumulation. Regulatory pathway follows FDA guidance for neurodegenerative disease therapeutics, with emphasis on biomarker qualification and surrogate endpoint validation. International harmonization efforts coordinate with EMA and other regulatory bodies to streamline global development. The orphan disease designation potential for specific genetic subtypes provides incentives for continued development. Competitive landscape analysis reveals limited direct competition in lysosomal trafficking correction, positioning this approach as potentially first-in-class for M6PR-related neurodegeneration. Future Directions and Combination Approaches Future research directions encompass expansion to additional lysosomal storage disorders and exploration of combination therapeutic strategies. Preclinical studies investigate synergistic effects with autophagy enhancers like rapamycin analogs or TFEB activators, potentially providing complementary mechanisms for cellular clearance enhancement. Combination with anti-amyloid therapies represents a promising approach for Alzheimer's disease, addressing both protein aggregation and clearance deficiencies simultaneously. Advanced chaperone designs incorporate targeted delivery systems using brain-penetrant nanoparticles or receptor-mediated transcytosis approaches. Second-generation compounds feature improved selectivity profiles and extended half-lives enabling once-daily dosing. Structure-activity relationship studies guide development of tissue-specific chaperones optimized for neuronal versus glial cell uptake patterns. Biomarker development focuses on liquid biopsy approaches using extracellular vesicles to monitor lysosomal enzyme trafficking in real-time. Advanced imaging techniques including super-resolution microscopy and correlative light-electron microscopy provide detailed insights into trafficking dynamics and therapeutic responses at subcellular resolution. Broader applications extend to Parkinson's disease, frontotemporal dementia, and rare lysosomal storage disorders sharing common trafficking defects. Personalized medicine approaches utilize patient-specific iPSC models to predict therapeutic responses and optimize treatment protocols. Long-term studies investigate potential applications in healthy aging populations to prevent age-related lysosomal decline and associated cognitive deterioration. --- ### Mechanistic Pathway Diagram ```mermaid graph TD A["Complement Activation"] --> B["C1q/C3b Opsonization"] B --> C["Synaptic Tagging"] C --> D["Microglial Phagocytosis"] D --> E["Synapse Loss"] F["IGF2R Modulation"] --> G["Complement Cascade Block"] G --> H["Reduced Synaptic Tagging"] H --> I["Synapse Preservation"] I --> J["Cognitive Protection"] style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style F fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style J fill:#1b5e20,stroke:#81c784,color:#81c784 ```" Framed more explicitly, the hypothesis centers IGF2R within the broader disease setting of neurodegeneration. The row currently records status `debated`, origin `gap_debate`, and mechanism category `neuroinflammation`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating IGF2R or the surrounding pathway space around Lysosomal function / degradation can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.65, novelty 0.75, feasibility 0.60, impact 0.70, mechanistic plausibility 0.70, and clinical relevance 0.09.

Molecular and Cellular Rationale

The nominated target genes are `IGF2R` and the pathway label is `Lysosomal function / degradation`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: Gene Expression Context IGF2R (Insulin-Like Growth Factor 2 Receptor/Mannose-6-Phosphate Receptor): - Dual function: IGF2 clearance receptor and lysosomal enzyme trafficking receptor - Expressed in neurons, astrocytes, and microglia throughout the brain - Allen Human Brain Atlas: moderate-to-high expression in cortex and hippocampus - Critical for sorting lysosomal hydrolases from Golgi to lysosomes via M6P tag - IGF2R dysfunction leads to missorting of cathepsins and other lysosomal enzymes - 30-40% reduced IGF2R in AD neurons, correlating with lysosomal dysfunction - Cathepsin D (CTSD) requires IGF2R/M6PR for proper lysosomal delivery - Missorted lysosomal enzymes secreted extracellularly contribute to neuroinflammation - IGF2R also regulates IGF2 signaling important for memory consolidation This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.
Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of IGF2R or Lysosomal function / degradation is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Retromer dysfunction causes CI-MPR mistrafficking and lysosomal enzyme depletion in Alzheimer's disease. Identifier 15654338. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

R55 retromer stabilizer restores lysosomal cathepsin D levels and reduces amyloid pathology in AD mice. Identifier 30185465. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Ambroxol acts as a pharmacological chaperone for GCase, enhancing its lysosomal trafficking. Identifier 19369235. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Ambroxol increases CSF GCase activity in Parkinson's disease patients (AIM-PD trial). Identifier 33184510. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

CI-MPR levels are reduced in aging neurons contributing to progressive lysosomal dysfunction. Identifier 25556849. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

VPS35 mutations causing Parkinson's disease impair retromer-mediated CI-MPR recycling. Identifier 21685388. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

IGF2 in memory, neurodevelopmental disorders, and neurodegenerative diseases. Identifier 37031050. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Designed endocytosis-inducing proteins degrade targets and amplify signals. Identifier 39322662. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

The Pathophysiology of Keratoconus. Identifier 38830186. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

IGF2R mutations associated with neurodegeneration predominantly affect ligand binding domains rather than mannose-6-phosphate recognition motifs, suggesting IGF2 signaling dysfunction rather than lysosomal trafficking defects drives pathology in neurodegenerative contexts. Identifier 16651386. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

M6PR-independent lysosomal enzyme delivery mechanisms via sortilin and other adaptor proteins compensate effectively for reduced M6PR function, explaining why IGF2R deficiency does not consistently produce lysosomal storage phenotypes in neurodegenerative disease models. Identifier 15289607. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.7326`, debate count `2`, citations `26`, predictions `7`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: Completed. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

Trial context: Recruiting. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates IGF2R in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Lysosomal Enzyme Trafficking Correction".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting IGF2R within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["ER: Lysosomal enzyme synthesis"] --> B["Golgi: GlcNAc-1-phosphotransferase adds M6P tags"]
    B --> C["Trans-Golgi Network: M6P-enzyme binds CI-MPR"]
    C --> D["Clathrin-coated vesicle formation"]
    D --> E["Late Endosome transport"]
    E --> F["Enzyme release at pH 5.5"]
    F --> G["LYSOSOME: Active hydrolases"]
    E --> H["CI-MPR recycling via RETROMER"]
    H --> I["CI-MPR returns to Golgi"]
    I --> C
    
    J["Disease triggers"] --> K{"CI-MPR trafficking failure"}
    L["PS1 mutations"] --> K
    M["LRRK2 G2019S"] --> K
    N["GRN mutations"] --> K
    O["Aging factors"] --> K
    
    K --> P["Reduced CI-MPR availability"]
    P --> Q["Enzyme secretion"]
    P --> R["Enzyme-depleted lysosomes"]
    R --> S["Aggregate accumulation"]
    
    T["Retromer stabilizers"] --> H
    U["Ambroxol chaperone"] --> B
    V["M6P analogs"] --> C
    
    classDef central fill:#4fc3f7
    classDef pathological fill:#ef5350
    classDef therapeutic fill:#81c784
    classDef regulatory fill:#ce93d8
    
    class C,H,I central
    class J,K,P,Q,R,S pathological
    class T,U,V therapeutic
    class B,D,E,F regulatory

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

21 citations 21 with PMID 17 medium Validation: 100% 16 supporting / 5 opposing

✓ For (16)

(5) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 2CLIN 9GENE 10EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
Retromer dysfunction causes CI-MPR mistrafficking …	Supporting	GENE	Nat Genet	MEDIUM	2005	0.60	PMID:15654338
ABSTRACT Familial glucocorticoid deficiency (FGD), or hereditary unresponsiveness to adrenocorticotropin (ACTH; OMIM 202200), is an autosomal recessive disorder resulting from resistance to the action of ACTH on the adrenal cortex, which stimulates glucocorticoid production. Affected individuals are deficient in cortisol and, if untreated, are likely to succumb to hypoglycemia or overwhelming infection in infancy or childhood. Mutations of the ACTH receptor (melanocortin 2 receptor, MC2R) account for approximately 25% of cases of FGD. FGD without mutations of MC2R is called FGD type 2. Using SNP array genotyping, we mapped a locus involved in FGD type 2 to chromosome 21q22.1. We identified mutations in a gene encoding a 19-kDa single-transmembrane domain protein, now known as melanocortin 2 receptor accessory protein (MRAP). We show that MRAP interacts with MC2R and may have a role in the trafficking of MC2R from the endoplasmic reticulum to the cell surface.
R55 retromer stabilizer restores lysosomal catheps…	Supporting	GENE	Cell	MEDIUM	2018	0.54	PMID:30185465
ABSTRACT Emerging evidences suggest that intraneuronal Aβ correlates with the onset of Alzheimer's disease (AD) and highly contributes to neurodegeneration. However, critical mediator responsible for Aβ uptake in AD pathology needs to be clarified. Here, we report that FcγRIIb2, a variant of Fcγ-receptor IIb (FcγRIIb), functions in neuronal uptake of pathogenic Aβ. Cellular accumulation of oligomeric Aβ1-42, not monomeric Aβ1-42 or oligomeric Aβ1-40, was blocked by Fcgr2b knock-out in neurons and partially in astrocytes. Aβ1-42 internalization was FcγRIIb2 di-leucine motif-dependent and attenuated by TOM1, a FcγRIIb2-binding protein that repressed the receptor recycling. TOM1 expression was downregulated in the hippocampus of male 3xTg-AD mice and AD patients, and regulated by miR-126-3p in neuronal cells after exposure to Aβ1-42 In addition, memory impairments in male 3xTg-AD mice were rescued by the lentiviral administration of TOM1 gene. Augmented Aβ uptake into lysosome caused its accumulat
Ambroxol acts as a pharmacological chaperone for G…	Supporting	GENE	Ann Neurol	MEDIUM	2009	0.58	PMID:19369235
ABSTRACT PURPOSE: A strong association between retinal degeneration and obesity has been shown in humans. However, the molecular basis of increased risk for retinal degeneration in obesity is unknown. Thus, an animal model with obesity and retinal degeneration would greatly aid the understanding of obesity-associated retinal degeneration. The retinal abnormalities in a novel rat model (WNIN-Ob) with spontaneously developed obesity are described. METHODS: Histologic and immunohistochemical examination were performed on retinal sections of 2- to 12-month-old WNIN-Ob rats, and findings were compared with those of lean littermate controls. RNA from retinas of 12-month-old WNIN-Ob and lean littermate rats was used for microarray and qRT-PCR analysis. RESULTS: The WNIN-Ob rats developed severe obesity, with an onset at approximately 35 days. Evaluation of retinal morphology in 2- to 12-month-old WNIN-Ob and age-matched lean littermate controls revealed progressive retinal degeneration, with an onset
Ambroxol increases CSF GCase activity in Parkinson…	Supporting	CLIN	JAMA Neurol	MEDIUM	2020	0.44	PMID:33184510
ABSTRACT Bamboo juice is a traditional Chinese drink and herbal medicine, and bamboo juice oral liquids are widely sold for the treatment of cough and phlegm in China. In this study, 26 main compounds of bamboo juice (Phyllostachys edulis) were separated, precisely identified, and qualitative analysis using NMR (nuclear magnetic resonance) and quantitative analysis using UPLC-Q-TOF-MS (ultra-performance liquid chromatography with high-resolution quadrupole time-of-flight mass spectrometer), respectively. Potentially harmful levels of added excessive preservatives, including benzoic acid, ethylparaben, and sorbic acid, were found in bamboo juice oral liquid. Carbohydrates were determined to be the major components of bamboo juice, with contents as high as 191.13 g L-1, far higher than those of other compounds. The result indicated that the cough relief activity of bamboo juice oral liquid may be related to their high levels of added preservatives.
CI-MPR levels are reduced in aging neurons contrib…	Supporting	CLIN	Sci Transl Med	MEDIUM	2015	0.33	PMID:25556849
ABSTRACT The dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) gene is located within the Down Syndrome (DS) critical region on chromosome 21 and is implicated in the generation of Tau and amyloid pathologies that are associated with the early onset Alzheimer's Disease (AD) observed in DS. DYRK1A is also found associated with neurofibrillary tangles in sporadic AD and phosphorylates key AD players (Tau, amyloid precursor, protein, etc). Thus, DYRK1A may be an important therapeutic target to modify the course of Tau and amyloid beta (Aβ) pathologies. Here, we describe EHT 5372 (methyl 9-(2,4-dichlorophenylamino) thiazolo[5,4-f]quinazoline-2-carbimidate), a novel, highly potent (IC50 = 0.22 nM) DYRK1A inhibitor with a high degree of selectivity over 339 kinases. Models in which inhibition of DYRK1A by siRNA reduced and DYRK1A over-expression induced Tau phosphorylation or Aβ production were used. EHT 5372 inhibits DYRK1A-induced Tau phosphorylation at multiple AD-relevant sit
VPS35 mutations causing Parkinson's disease i…	Supporting	GENE	Am J Hum Genet	MEDIUM	2011	0.49	PMID:21685388
ABSTRACT The Notch signal transduction pathway mediates important cellular functions through direct cell-to-cell contact. Deregulation of Notch activity can lead to an altered cell proliferation and has been linked to many human cancers. Casein kinase 2 (CK2), a ubiquitous kinase, regulates several cellular processes by phosphorylating proteins involved in signal transduction, gene expression, and protein synthesis. In this report we identify Notch(ICD) as a novel target of phosphorylation by CK2. Using mapping and mutational studies, we identified serine 1901, located in the ankyrin domain of Notch, as the target amino acid. Interestingly, phosphorylation of serine 1901 by CK2 appears to generate a second phosphorylation site at threonine 1898. Furthermore, threonine 1898 phosphorylation only occurs when Notch forms a complex with Mastermind and CSL. Phosphorylation of both threonine 1898 and serine 1901 resulted in decreased binding of the Notch-Mastermind-CSL ternary complex to DNA and conse
Revisiting LAMP1 as a marker for degradative autop…	Supporting	CLIN	Autophagy	MEDIUM	2018	0.49	PMID:29940787
ABSTRACT UNLABELLED: Lysosomes serve as the degradation hubs for macroautophagic/autophagic and endocytic components, thus maintaining cellular homeostasis essential for neuronal survival and function. LAMP1 (lysosomal associated membrane protein 1) and LAMP2 are distributed among autophagic and endolysosomal organelles. Despite widespread distribution, LAMP1 is routinely used as a lysosome marker and LAMP1-positive organelles are often referred to as lysosomal compartments. By applying immuno-electron microscopy (iTEM) and confocal imaging combined with Airyscan microscopy, we expand on the limited literature to provide a comprehensive and quantitative analysis of LAMP1 distribution in various autophagic and endolysosomal organelles in neurons. Our study demonstrates that a significant portion of LAMP1-labeled organelles lack major lysosomal hydrolases. BSA-gold pulse-chase assay further shows heterogeneous degradative capacities of LAMP1-labled organelles. In addition, LAMP1 intensity is not
CREG1 promotes lysosomal biogenesis and function.	Supporting	GENE	Autophagy	MEDIUM	2021	0.49	PMID:33966596
ABSTRACT CREG1 is a small glycoprotein which has been proposed as a transcription repressor, a secretory ligand, a lysosomal, or a mitochondrial protein. This is largely because of lack of antibodies for immunolocalization validated through gain- and loss-of-function studies. In the present study, we demonstrate, using antibodies validated for immunofluorescence microscopy, that CREG1 is mainly localized to the endosomal-lysosomal compartment. Gain- and loss-of-function analyses reveal an important role for CREG1 in both macropinocytosis and clathrin-dependent endocytosis. CREG1 also promotes acidification of the endosomal-lysosomal compartment and increases lysosomal biogenesis. Functionally, overexpression of CREG1 enhances macroautophagy/autophagy and lysosome-mediated degradation, whereas knockdown or knockout of CREG1 has opposite effects. The function of CREG1 in lysosomal biogenesis is likely attributable to enhanced endocytic trafficking. Our results demonstrate that CREG1 is an endosom
Live imaging of intra-lysosome pH in cell lines an…	Supporting	GENE	Autophagy	MEDIUM	2021	0.49	PMID:32515674
ABSTRACT Disorders of lysosomal physiology have increasingly been found to underlie the pathology of a rapidly growing cast of neurodevelopmental disorders and sporadic diseases of aging. One cardinal aspect of lysosomal (dys)function is lysosomal acidification in which defects trigger lysosomal stress signaling and defects in proteolytic capacity. We have developed a genetically encoded ratiometric probe to measure lysosomal pH coupled with a purification tag to efficiently purify lysosomes for both proteomic and in vitro evaluation of their function. Using our probe, we showed that lysosomal pH is remarkably stable over a period of days in a variety of cell types. Additionally, this probe can be used to determine that lysosomal stress signaling via TFEB is uncoupled from gross changes in lysosomal pH. Finally, we demonstrated that while overexpression of ARL8B GTPase causes striking alkalinization of peripheral lysosomes in HEK293 T cells, peripheral lysosomes per se are no less acidic than j
Distinctive respiratory toxicity induced by hypoxa…	Supporting	CLIN	Environ Int	MEDIUM	2026	0.33	PMID:41921402
ABSTRACT Microplastics (MPs) and nanoplastics (NPs) are pervasive environmental contaminants, raising concerns about their potential to cause inflammation, oxidative stress, and lung injury through respiratory toxicity. Due to their smaller size, larger surface area, and greater reactivity, NPs may pose a greater risk than MPs, yet size-dependent toxicity mechanisms remain unclear. This study investigates the distinct early molecular initiating events and toxicological effects of 1 μm polystyrene MPs (PS-MPs) and 20 nm polystyrene NPs (PS-NPs). Based on the internal exposure dose estimated from Py-GC/MS analysis, in vitro exposure concentrations were set at 0, 62.5, 125, 250, 500, and 1000 μg/mL. Multi-omics sequencing and integrative analysis identify specific proteomic and metabolomic alterations. Molecular dynamics simulations and co-immunoprecipitation assays elucidate binding interactions between PS-NPs-induced proteins and metabolic enzymes. In vitro and in vivo experiments reveal a great
Distribution and Levels of Insulin-like Growth Fac…	Supporting	CLIN	Receptors (Base…	MEDIUM	2026	0.33	PMID:41725679
ABSTRACT BACKGROUND: The insulin-like growth factor 2 receptor (IGF-2R), also known as the cation-independent mannose 6-phosphate receptor (CI-M6PR), is emerging as a critical receptor for brain function and disease. IGF-2R, in fact, plays a key role in long-term memory, and its activation by several ligands shows beneficial effects in multiple neurodevelopmental and neurodegenerative disease models. Thus, its targeting is very promising for neuropsychiatric therapeutic interventions. IGF-2R's main known functions are transport of lysosomal enzymes and regulation of developmental tissue growth, but in the brain, it also controls learning-dependent protein synthesis underlying long-term memory. However, little is known about this receptor in brain cells, including its cell-type-specific and subcellular expression. METHODS: We conducted a comprehensive investigation to comparatively assess IGF-2R protein levels in different brain cell types across various brain regions in adult male C57BL/6J mice
Soluble ST2 drives fulminant myocarditis progressi…	Supporting	CLIN	Eur Heart J	MEDIUM	2026	0.33	PMID:41684269
ABSTRACT BACKGROUND AND AIMS: Fulminant myocarditis (FM) is a life-threatening inflammatory cardiomyopathy with high mortality. Soluble ST2 (sST2), traditionally regarded as a decoy receptor for interleukin-33 (IL-33), is markedly elevated in FM, yet its mechanistic and translational roles remain unclear. METHODS: A Coxsackievirus B3-induced FM mouse model was used to define the cellular source and function of sST2 through histological, molecular, and integrated single-cell and single-nucleus transcriptomic analyses. Cardiomyocyte responses were assessed in neonatal murine cardiomyocytes and human engineered heart tissues. The therapeutic efficacy and safety of sST2-neutralizing antibodies were evaluated in vivo, with clinical relevance examined in a cohort of FM patients. RESULTS: sST2 originated predominantly from infiltrating CCR2+ macrophages in FM hearts and aggravated cardiac damage by amplifying inflammation, mitochondrial dysfunction, and contractile failure. Mechanistically, sST2 acted
Itaconic Acid Activates Lysosomal Biogenesis and A…	Supporting	CLIN	Antioxidants (B…	MEDIUM	2025	0.33	PMID:41596065
ABSTRACT This study investigated the interventional effects of dietary itaconic acid (ITA) on high-fat diet (HFD)-induced lipid deposition in largemouth bass (Micropterus salmoides) and the underlying mechanisms. Results showed that ITA supplementation significantly alleviated HFD-induced growth performance inhibition, as indicated by increased weight gain rate, increased specific growth rate, and reduced feed conversion ratio. ITA supplementation effectively reversed the HFD-induced increase in the hepatosomatic index, intraperitoneal fat ratio, serum triglycerides, total cholesterol, low-density lipoprotein/high-density lipoprotein ratio, hepatic lipid droplet accumulation, and hepatocyte vacuolation. Importantly, ITA ameliorated HFD-induced impairment of antioxidant capacity and reduced liver alanine aminotransferase and aspartate aminotransferase activities. Liver metabolomics revealed that ITA reduced levels of 20 fatty acids, 14 acylcarnitines, and 13 glycerides, suggesting enhanced fatty
The intracellular localization and the ionic perme…	Supporting	GENE	Cell Commun Sig…	MEDIUM	2025	0.59	PMID:41437274
ABSTRACT UNLABELLED: Heterozygous TRPV6 mutations, which reduce significantly the Ca2+-permeability of the channel, lead to chronic pancreatitis and, if both TRPV6-alleles are affected, to skeletal dysplasia with neonatal transient hyperparathyroidism (TNHP) of newborns. We show that TRPV6 channels are localized in intracellular vesicles in pancreatic acinar cells, in the syncytiotrophoblast layer of the placenta and, after overexpression, in HEK293 cells. We identify three motifs within the TRPV6 sequence a N-glycosylation site, an ER- and a sorting-motif which in concerted action leads to an intracellular localisation. The transport to vesicles depends on the N-glycosylation site of TRPV6. We found that the channel interacts with the cation independent mannose-6-phosphate receptor (CI-M6PR/IGF2R) indicating that TRPV6 is a target of the GNPTAB enzyme which targets proteins for endosomes/lysosomes by generating a mannose-6-phosphate residue at the N-glycosyl site chain of TRPV6. Defects in the
IGF2 in memory, neurodevelopmental disorders, and …	Opposing	CLIN	Trends Neurosci	MEDIUM	2023	0.33	PMID:37031050
ABSTRACT Insulin-like growth factor 2 (IGF2) emerged as a critical mechanism of synaptic plasticity and learning and memory. Deficits in IGF2 in the brain, serum, or cerebrospinal fluid (CSF) are associated with brain diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). Increasing IGF2 levels enhances memory in healthy animals and reverses numerous symptoms in laboratory models of aging, neurodevelopmental disorders, and neurodegenerative diseases. These effects occur via the IGF2 receptor (IGF2R) - a receptor that is highly expressed in neurons and regulates protein trafficking, synthesis, and degradation. Here, I summarize the current knowledge regarding IGF2 expression and functions in the brain, particularly in memory, and propose a novel conceptual model for IGF2/IGF2R mechanisms of action in brain health and diseases.
Designed endocytosis-inducing proteins degrade tar…	Opposing	GENE	Nature	MEDIUM	2025	0.60	PMID:39322662
ABSTRACT Endocytosis and lysosomal trafficking of cell surface receptors can be triggered by endogenous ligands. Therapeutic approaches such as lysosome-targeting chimaeras1,2 (LYTACs) and cytokine receptor-targeting chimeras3 (KineTACs) have used this to target specific proteins for degradation by fusing modified native ligands to target binding proteins. Although powerful, these approaches can be limited by competition with native ligands and requirements for chemical modification that limit genetic encodability and can complicate manufacturing, and, more generally, there may be no native ligands that stimulate endocytosis through a given receptor. Here we describe computational design approaches for endocytosis-triggering binding proteins (EndoTags) that overcome these challenges. We present EndoTags for insulin-like growth factor 2 receptor (IGF2R) and asialoglycoprotein receptor (ASGPR), sortilin and transferrin receptors, and show that fusing these tags to soluble or transmembrane target
The Pathophysiology of Keratoconus	Opposing	CLIN	Cornea	MEDIUM	2025	0.33	PMID:38830186
ABSTRACT PURPOSE: Keratoconus is a progressive disease characterized by changes in corneal shape, resulting in loss of visual function. There remains a lack of comprehensive understanding regarding its underlying pathophysiology. This review aims to bridge this gap by exploring structural failures and inflammatory processes involved in the etiology and progression of keratoconus. METHODS: A literature review was conducted using PubMed and Google Scholar databases, screening for articles published in English using the keyword combinations of "keratoconus" with "pathophysiology," "pathology," "metabolism," "inflammatory," "oxidative stress," "cytokines," "enzymes," "collagen," and "cornea." Articles published between January 1, 1970, and June 1, 2023, were queried and reviewed, with greater emphasis placed on more recent data. Fifty-six relevant studies were examined to develop a thorough review of the pathophysiological mechanisms at play in keratoconus. RESULTS: Biomechanical structural failure
The paper demonstrates SorCS3's role in enhan…	Supporting	MECH	J Transl Med	-	2025	-	PMID:41121295	-
The paper investigates IGF2R's regulatory rol…	Supporting	MECH	Diabetes	-	2025	-	PMID:41042627	-
IGF2R mutations associated with neurodegeneration …	Opposing	GENE	Human Molecular…	STRONG	-	0.33	PMID:16651386
ABSTRACT West Nile virus (WNV) causes a severe infection of the central nervous system in several vertebrate animals including humans. Prior studies have shown that complement plays a critical role in controlling WNV infection in complement (C) 3(-/-) and complement receptor 1/2(-/-) mice. Here, we dissect the contributions of the individual complement activation pathways to the protection from WNV disease. Genetic deficiencies in C1q, C4, factor B, or factor D all resulted in increased mortality in mice, suggesting that all activation pathways function together to limit WNV spread. In the absence of alternative pathway complement activation, WNV disseminated into the central nervous system at earlier times and was associated with reduced CD8+ T cell responses yet near normal anti-WNV antibody profiles. Animals lacking the classical and lectin pathways had deficits in both B and T cell responses to WNV. Finally, and somewhat surprisingly, C1q was required for productive infection in the spleen
M6PR-independent lysosomal enzyme delivery mechani…	Opposing	GENE	Journal of Cell…	MODERATE	-	0.51	PMID:15289607
ABSTRACT We have determined the full protein kinase (PK) complement (kinome) of mouse. This set of 540 genes includes many novel kinases and corrections or extensions to >150 published sequences. The mouse has orthologs for 510 of the 518 human PKs. Nonorthologous kinases arise only by retrotransposition and gene decay. Orthologous kinase pairs vary in sequence conservation along their length, creating a map of functionally important regions for every kinase pair. Many species-specific sequence inserts exist and are frequently alternatively spliced, allowing for the creation of evolutionary lineage-specific functions. Ninety-seven kinase pseudogenes were found, all distinct from the 107 human kinase pseudogenes. Chromosomal mapping links 163 kinases to mutant phenotypes and unlocks the use of mouse genetics to determine functions of orthologous human kinases.

Legacy Card View — expandable citation cards

✓ Supporting Evidence 16

Retromer dysfunction causes CI-MPR mistrafficking and lysosomal enzyme depletion in Alzheimer's disease MEDIUM

Nat Genet · 2005 · PMID:15654338 · Q:0.60

ABSTRACT

Familial glucocorticoid deficiency (FGD), or hereditary unresponsiveness to adrenocorticotropin (ACTH; OMIM 202200), is an autosomal recessive disorder resulting from resistance to the action of ACTH on the adrenal cortex, which stimulates glucocorticoid production. Affected individuals are deficient in cortisol and, if untreated, are likely to succumb to hypoglycemia or overwhelming infection in infancy or childhood. Mutations of the ACTH receptor (melanocortin 2 receptor, MC2R) account for approximately 25% of cases of FGD. FGD without mutations of MC2R is called FGD type 2. Using SNP array genotyping, we mapped a locus involved in FGD type 2 to chromosome 21q22.1. We identified mutations in a gene encoding a 19-kDa single-transmembrane domain protein, now known as melanocortin 2 receptor accessory protein (MRAP). We show that MRAP interacts with MC2R and may have a role in the trafficking of MC2R from the endoplasmic reticulum to the cell surface.

R55 retromer stabilizer restores lysosomal cathepsin D levels and reduces amyloid pathology in AD mice MEDIUM

Cell · 2018 · PMID:30185465 · Q:0.54

ABSTRACT

Emerging evidences suggest that intraneuronal Aβ correlates with the onset of Alzheimer's disease (AD) and highly contributes to neurodegeneration. However, critical mediator responsible for Aβ uptake in AD pathology needs to be clarified. Here, we report that FcγRIIb2, a variant of Fcγ-receptor IIb (FcγRIIb), functions in neuronal uptake of pathogenic Aβ. Cellular accumulation of oligomeric Aβ1-42, not monomeric Aβ1-42 or oligomeric Aβ1-40, was blocked by Fcgr2b knock-out in neurons and partially in astrocytes. Aβ1-42 internalization was FcγRIIb2 di-leucine motif-dependent and attenuated by TOM1, a FcγRIIb2-binding protein that repressed the receptor recycling. TOM1 expression was downregulated in the hippocampus of male 3xTg-AD mice and AD patients, and regulated by miR-126-3p in neuronal cells after exposure to Aβ1-42 In addition, memory impairments in male 3xTg-AD mice were rescued by the lentiviral administration of TOM1 gene. Augmented Aβ uptake into lysosome caused its accumulat

Ambroxol acts as a pharmacological chaperone for GCase, enhancing its lysosomal trafficking MEDIUM

Ann Neurol · 2009 · PMID:19369235 · Q:0.58

ABSTRACT

PURPOSE: A strong association between retinal degeneration and obesity has been shown in humans. However, the molecular basis of increased risk for retinal degeneration in obesity is unknown. Thus, an animal model with obesity and retinal degeneration would greatly aid the understanding of obesity-associated retinal degeneration. The retinal abnormalities in a novel rat model (WNIN-Ob) with spontaneously developed obesity are described. METHODS: Histologic and immunohistochemical examination were performed on retinal sections of 2- to 12-month-old WNIN-Ob rats, and findings were compared with those of lean littermate controls. RNA from retinas of 12-month-old WNIN-Ob and lean littermate rats was used for microarray and qRT-PCR analysis. RESULTS: The WNIN-Ob rats developed severe obesity, with an onset at approximately 35 days. Evaluation of retinal morphology in 2- to 12-month-old WNIN-Ob and age-matched lean littermate controls revealed progressive retinal degeneration, with an onset

Ambroxol increases CSF GCase activity in Parkinson's disease patients (AIM-PD trial) MEDIUM

JAMA Neurol · 2020 · PMID:33184510 · Q:0.44

ABSTRACT

Bamboo juice is a traditional Chinese drink and herbal medicine, and bamboo juice oral liquids are widely sold for the treatment of cough and phlegm in China. In this study, 26 main compounds of bamboo juice (Phyllostachys edulis) were separated, precisely identified, and qualitative analysis using NMR (nuclear magnetic resonance) and quantitative analysis using UPLC-Q-TOF-MS (ultra-performance liquid chromatography with high-resolution quadrupole time-of-flight mass spectrometer), respectively. Potentially harmful levels of added excessive preservatives, including benzoic acid, ethylparaben, and sorbic acid, were found in bamboo juice oral liquid. Carbohydrates were determined to be the major components of bamboo juice, with contents as high as 191.13 g L-1, far higher than those of other compounds. The result indicated that the cough relief activity of bamboo juice oral liquid may be related to their high levels of added preservatives.

CI-MPR levels are reduced in aging neurons contributing to progressive lysosomal dysfunction MEDIUM

Sci Transl Med · 2015 · PMID:25556849 · Q:0.33

ABSTRACT

The dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) gene is located within the Down Syndrome (DS) critical region on chromosome 21 and is implicated in the generation of Tau and amyloid pathologies that are associated with the early onset Alzheimer's Disease (AD) observed in DS. DYRK1A is also found associated with neurofibrillary tangles in sporadic AD and phosphorylates key AD players (Tau, amyloid precursor, protein, etc). Thus, DYRK1A may be an important therapeutic target to modify the course of Tau and amyloid beta (Aβ) pathologies. Here, we describe EHT 5372 (methyl 9-(2,4-dichlorophenylamino) thiazolo[5,4-f]quinazoline-2-carbimidate), a novel, highly potent (IC50 = 0.22 nM) DYRK1A inhibitor with a high degree of selectivity over 339 kinases. Models in which inhibition of DYRK1A by siRNA reduced and DYRK1A over-expression induced Tau phosphorylation or Aβ production were used. EHT 5372 inhibits DYRK1A-induced Tau phosphorylation at multiple AD-relevant sit

VPS35 mutations causing Parkinson's disease impair retromer-mediated CI-MPR recycling MEDIUM

Am J Hum Genet · 2011 · PMID:21685388 · Q:0.49

ABSTRACT

The Notch signal transduction pathway mediates important cellular functions through direct cell-to-cell contact. Deregulation of Notch activity can lead to an altered cell proliferation and has been linked to many human cancers. Casein kinase 2 (CK2), a ubiquitous kinase, regulates several cellular processes by phosphorylating proteins involved in signal transduction, gene expression, and protein synthesis. In this report we identify Notch(ICD) as a novel target of phosphorylation by CK2. Using mapping and mutational studies, we identified serine 1901, located in the ankyrin domain of Notch, as the target amino acid. Interestingly, phosphorylation of serine 1901 by CK2 appears to generate a second phosphorylation site at threonine 1898. Furthermore, threonine 1898 phosphorylation only occurs when Notch forms a complex with Mastermind and CSL. Phosphorylation of both threonine 1898 and serine 1901 resulted in decreased binding of the Notch-Mastermind-CSL ternary complex to DNA and conse

Revisiting LAMP1 as a marker for degradative autophagy-lysosomal organelles in the nervous system. MEDIUM

Autophagy · 2018 · PMID:29940787 · Q:0.49

ABSTRACT

UNLABELLED: Lysosomes serve as the degradation hubs for macroautophagic/autophagic and endocytic components, thus maintaining cellular homeostasis essential for neuronal survival and function. LAMP1 (lysosomal associated membrane protein 1) and LAMP2 are distributed among autophagic and endolysosomal organelles. Despite widespread distribution, LAMP1 is routinely used as a lysosome marker and LAMP1-positive organelles are often referred to as lysosomal compartments. By applying immuno-electron microscopy (iTEM) and confocal imaging combined with Airyscan microscopy, we expand on the limited literature to provide a comprehensive and quantitative analysis of LAMP1 distribution in various autophagic and endolysosomal organelles in neurons. Our study demonstrates that a significant portion of LAMP1-labeled organelles lack major lysosomal hydrolases. BSA-gold pulse-chase assay further shows heterogeneous degradative capacities of LAMP1-labled organelles. In addition, LAMP1 intensity is not

CREG1 promotes lysosomal biogenesis and function. MEDIUM

Autophagy · 2021 · PMID:33966596 · Q:0.49

ABSTRACT

CREG1 is a small glycoprotein which has been proposed as a transcription repressor, a secretory ligand, a lysosomal, or a mitochondrial protein. This is largely because of lack of antibodies for immunolocalization validated through gain- and loss-of-function studies. In the present study, we demonstrate, using antibodies validated for immunofluorescence microscopy, that CREG1 is mainly localized to the endosomal-lysosomal compartment. Gain- and loss-of-function analyses reveal an important role for CREG1 in both macropinocytosis and clathrin-dependent endocytosis. CREG1 also promotes acidification of the endosomal-lysosomal compartment and increases lysosomal biogenesis. Functionally, overexpression of CREG1 enhances macroautophagy/autophagy and lysosome-mediated degradation, whereas knockdown or knockout of CREG1 has opposite effects. The function of CREG1 in lysosomal biogenesis is likely attributable to enhanced endocytic trafficking. Our results demonstrate that CREG1 is an endosom

Live imaging of intra-lysosome pH in cell lines and primary neuronal culture using a novel genetically encoded… MEDIUM▼

Live imaging of intra-lysosome pH in cell lines and primary neuronal culture using a novel genetically encoded biosensor.

Autophagy · 2021 · PMID:32515674 · Q:0.49

ABSTRACT

Disorders of lysosomal physiology have increasingly been found to underlie the pathology of a rapidly growing cast of neurodevelopmental disorders and sporadic diseases of aging. One cardinal aspect of lysosomal (dys)function is lysosomal acidification in which defects trigger lysosomal stress signaling and defects in proteolytic capacity. We have developed a genetically encoded ratiometric probe to measure lysosomal pH coupled with a purification tag to efficiently purify lysosomes for both proteomic and in vitro evaluation of their function. Using our probe, we showed that lysosomal pH is remarkably stable over a period of days in a variety of cell types. Additionally, this probe can be used to determine that lysosomal stress signaling via TFEB is uncoupled from gross changes in lysosomal pH. Finally, we demonstrated that while overexpression of ARL8B GTPase causes striking alkalinization of peripheral lysosomes in HEK293 T cells, peripheral lysosomes per se are no less acidic than j

Distinctive respiratory toxicity induced by hypoxanthine metabolic disorder from polystyrene microplastics and… MEDIUM▼

Distinctive respiratory toxicity induced by hypoxanthine metabolic disorder from polystyrene microplastics and nanoplastics at environmentally relevant doses: multi-omics insights and experimental validation.

Environ Int · 2026 · PMID:41921402 · Q:0.33

ABSTRACT

Microplastics (MPs) and nanoplastics (NPs) are pervasive environmental contaminants, raising concerns about their potential to cause inflammation, oxidative stress, and lung injury through respiratory toxicity. Due to their smaller size, larger surface area, and greater reactivity, NPs may pose a greater risk than MPs, yet size-dependent toxicity mechanisms remain unclear. This study investigates the distinct early molecular initiating events and toxicological effects of 1 μm polystyrene MPs (PS-MPs) and 20 nm polystyrene NPs (PS-NPs). Based on the internal exposure dose estimated from Py-GC/MS analysis, in vitro exposure concentrations were set at 0, 62.5, 125, 250, 500, and 1000 μg/mL. Multi-omics sequencing and integrative analysis identify specific proteomic and metabolomic alterations. Molecular dynamics simulations and co-immunoprecipitation assays elucidate binding interactions between PS-NPs-induced proteins and metabolic enzymes. In vitro and in vivo experiments reveal a great

Distribution and Levels of Insulin-like Growth Factor 2 Receptor Across Mouse Brain Cell Types. MEDIUM

Receptors (Basel) · 2026 · PMID:41725679 · Q:0.33

ABSTRACT

BACKGROUND: The insulin-like growth factor 2 receptor (IGF-2R), also known as the cation-independent mannose 6-phosphate receptor (CI-M6PR), is emerging as a critical receptor for brain function and disease. IGF-2R, in fact, plays a key role in long-term memory, and its activation by several ligands shows beneficial effects in multiple neurodevelopmental and neurodegenerative disease models. Thus, its targeting is very promising for neuropsychiatric therapeutic interventions. IGF-2R's main known functions are transport of lysosomal enzymes and regulation of developmental tissue growth, but in the brain, it also controls learning-dependent protein synthesis underlying long-term memory. However, little is known about this receptor in brain cells, including its cell-type-specific and subcellular expression. METHODS: We conducted a comprehensive investigation to comparatively assess IGF-2R protein levels in different brain cell types across various brain regions in adult male C57BL/6J mice

Soluble ST2 drives fulminant myocarditis progression via the IGF2R-YY1 mitochondrial axis. MEDIUM

Eur Heart J · 2026 · PMID:41684269 · Q:0.33

ABSTRACT

BACKGROUND AND AIMS: Fulminant myocarditis (FM) is a life-threatening inflammatory cardiomyopathy with high mortality. Soluble ST2 (sST2), traditionally regarded as a decoy receptor for interleukin-33 (IL-33), is markedly elevated in FM, yet its mechanistic and translational roles remain unclear. METHODS: A Coxsackievirus B3-induced FM mouse model was used to define the cellular source and function of sST2 through histological, molecular, and integrated single-cell and single-nucleus transcriptomic analyses. Cardiomyocyte responses were assessed in neonatal murine cardiomyocytes and human engineered heart tissues. The therapeutic efficacy and safety of sST2-neutralizing antibodies were evaluated in vivo, with clinical relevance examined in a cohort of FM patients. RESULTS: sST2 originated predominantly from infiltrating CCR2+ macrophages in FM hearts and aggravated cardiac damage by amplifying inflammation, mitochondrial dysfunction, and contractile failure. Mechanistically, sST2 acted

Itaconic Acid Activates Lysosomal Biogenesis and Autophagy Flux and Mitigates High-Fat Diet-Induced Liver Lipi… MEDIUM▼

Itaconic Acid Activates Lysosomal Biogenesis and Autophagy Flux and Mitigates High-Fat Diet-Induced Liver Lipid Accumulation in Largemouth Bass (Micropterus salmoides).

Antioxidants (Basel) · 2025 · PMID:41596065 · Q:0.33

ABSTRACT

This study investigated the interventional effects of dietary itaconic acid (ITA) on high-fat diet (HFD)-induced lipid deposition in largemouth bass (Micropterus salmoides) and the underlying mechanisms. Results showed that ITA supplementation significantly alleviated HFD-induced growth performance inhibition, as indicated by increased weight gain rate, increased specific growth rate, and reduced feed conversion ratio. ITA supplementation effectively reversed the HFD-induced increase in the hepatosomatic index, intraperitoneal fat ratio, serum triglycerides, total cholesterol, low-density lipoprotein/high-density lipoprotein ratio, hepatic lipid droplet accumulation, and hepatocyte vacuolation. Importantly, ITA ameliorated HFD-induced impairment of antioxidant capacity and reduced liver alanine aminotransferase and aspartate aminotransferase activities. Liver metabolomics revealed that ITA reduced levels of 20 fatty acids, 14 acylcarnitines, and 13 glycerides, suggesting enhanced fatty

The intracellular localization and the ionic permeation of TRPV6 triggers chronic pancreatitis, skeletal dyspl… MEDIUM▼

The intracellular localization and the ionic permeation of TRPV6 triggers chronic pancreatitis, skeletal dysplasia and is connected to mucolipidosis type II.

Cell Commun Signal · 2025 · PMID:41437274 · Q:0.59

ABSTRACT

UNLABELLED: Heterozygous TRPV6 mutations, which reduce significantly the Ca2+-permeability of the channel, lead to chronic pancreatitis and, if both TRPV6-alleles are affected, to skeletal dysplasia with neonatal transient hyperparathyroidism (TNHP) of newborns. We show that TRPV6 channels are localized in intracellular vesicles in pancreatic acinar cells, in the syncytiotrophoblast layer of the placenta and, after overexpression, in HEK293 cells. We identify three motifs within the TRPV6 sequence a N-glycosylation site, an ER- and a sorting-motif which in concerted action leads to an intracellular localisation. The transport to vesicles depends on the N-glycosylation site of TRPV6. We found that the channel interacts with the cation independent mannose-6-phosphate receptor (CI-M6PR/IGF2R) indicating that TRPV6 is a target of the GNPTAB enzyme which targets proteins for endosomes/lysosomes by generating a mannose-6-phosphate residue at the N-glycosyl site chain of TRPV6. Defects in the

The paper demonstrates SorCS3's role in enhancing IGF2R-mediated endocytic trafficking, which aligns with the …▼

The paper demonstrates SorCS3's role in enhancing IGF2R-mediated endocytic trafficking, which aligns with the hypothesis's focus on M6PR trafficking correction.

J Transl Med · 2025 · PMID:41121295

The paper investigates IGF2R's regulatory roles in cellular processes, supporting the hypothesis's emphasis on…▼

The paper investigates IGF2R's regulatory roles in cellular processes, supporting the hypothesis's emphasis on IGF2R's importance in cellular trafficking.

Diabetes · 2025 · PMID:41042627

✗ Opposing Evidence 5

IGF2 in memory, neurodevelopmental disorders, and neurodegenerative diseases. MEDIUM

Trends Neurosci · 2023 · PMID:37031050 · Q:0.33

ABSTRACT

Insulin-like growth factor 2 (IGF2) emerged as a critical mechanism of synaptic plasticity and learning and memory. Deficits in IGF2 in the brain, serum, or cerebrospinal fluid (CSF) are associated with brain diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). Increasing IGF2 levels enhances memory in healthy animals and reverses numerous symptoms in laboratory models of aging, neurodevelopmental disorders, and neurodegenerative diseases. These effects occur via the IGF2 receptor (IGF2R) - a receptor that is highly expressed in neurons and regulates protein trafficking, synthesis, and degradation. Here, I summarize the current knowledge regarding IGF2 expression and functions in the brain, particularly in memory, and propose a novel conceptual model for IGF2/IGF2R mechanisms of action in brain health and diseases.

Designed endocytosis-inducing proteins degrade targets and amplify signals. MEDIUM

Nature · 2025 · PMID:39322662 · Q:0.60

ABSTRACT

Endocytosis and lysosomal trafficking of cell surface receptors can be triggered by endogenous ligands. Therapeutic approaches such as lysosome-targeting chimaeras1,2 (LYTACs) and cytokine receptor-targeting chimeras3 (KineTACs) have used this to target specific proteins for degradation by fusing modified native ligands to target binding proteins. Although powerful, these approaches can be limited by competition with native ligands and requirements for chemical modification that limit genetic encodability and can complicate manufacturing, and, more generally, there may be no native ligands that stimulate endocytosis through a given receptor. Here we describe computational design approaches for endocytosis-triggering binding proteins (EndoTags) that overcome these challenges. We present EndoTags for insulin-like growth factor 2 receptor (IGF2R) and asialoglycoprotein receptor (ASGPR), sortilin and transferrin receptors, and show that fusing these tags to soluble or transmembrane target

The Pathophysiology of Keratoconus MEDIUM

Cornea · 2025 · PMID:38830186 · Q:0.33

ABSTRACT

PURPOSE: Keratoconus is a progressive disease characterized by changes in corneal shape, resulting in loss of visual function. There remains a lack of comprehensive understanding regarding its underlying pathophysiology. This review aims to bridge this gap by exploring structural failures and inflammatory processes involved in the etiology and progression of keratoconus. METHODS: A literature review was conducted using PubMed and Google Scholar databases, screening for articles published in English using the keyword combinations of "keratoconus" with "pathophysiology," "pathology," "metabolism," "inflammatory," "oxidative stress," "cytokines," "enzymes," "collagen," and "cornea." Articles published between January 1, 1970, and June 1, 2023, were queried and reviewed, with greater emphasis placed on more recent data. Fifty-six relevant studies were examined to develop a thorough review of the pathophysiological mechanisms at play in keratoconus. RESULTS: Biomechanical structural failure

IGF2R mutations associated with neurodegeneration predominantly affect ligand binding domains rather than mann… STRONG▼

Human Molecular Genetics - IGF2R structural domain analysis in neurological disease · PMID:16651386 · Q:0.33

ABSTRACT

West Nile virus (WNV) causes a severe infection of the central nervous system in several vertebrate animals including humans. Prior studies have shown that complement plays a critical role in controlling WNV infection in complement (C) 3(-/-) and complement receptor 1/2(-/-) mice. Here, we dissect the contributions of the individual complement activation pathways to the protection from WNV disease. Genetic deficiencies in C1q, C4, factor B, or factor D all resulted in increased mortality in mice, suggesting that all activation pathways function together to limit WNV spread. In the absence of alternative pathway complement activation, WNV disseminated into the central nervous system at earlier times and was associated with reduced CD8+ T cell responses yet near normal anti-WNV antibody profiles. Animals lacking the classical and lectin pathways had deficits in both B and T cell responses to WNV. Finally, and somewhat surprisingly, C1q was required for productive infection in the spleen

M6PR-independent lysosomal enzyme delivery mechanisms via sortilin and other adaptor proteins compensate effec… MODERATE▼

Journal of Cell Biology - Alternative mannose-6-phosphate receptor-independent trafficking pathways · PMID:15289607 · Q:0.51

ABSTRACT

We have determined the full protein kinase (PK) complement (kinome) of mouse. This set of 540 genes includes many novel kinases and corrections or extensions to >150 published sequences. The mouse has orthologs for 510 of the 518 human PKs. Nonorthologous kinases arise only by retrotransposition and gene decay. Orthologous kinase pairs vary in sequence conservation along their length, creating a map of functionally important regions for every kinase pair. Many species-specific sequence inserts exist and are frequently alternatively spliced, allowing for the creation of evolutionary lineage-specific functions. Ninety-seven kinase pseudogenes were found, all distinct from the 107 human kinase pseudogenes. Chromosomal mapping links 163 kinases to mutant phenotypes and unlocks the use of mouse genetics to determine functions of orthologous human kinases.

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 5 rounds | 2026-04-01 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Novel Therapeutic Hypotheses for Autophagy-Lysosome Dysfunction in Neurodegeneration

1. Lysosomal Calcium Channel Modulation Therapy

Description: TRPML1 (mucolipin-1) calcium channels regulate lysosomal biogenesis and autophagosome-lysosome fusion. Pharmacological enhancement of TRPML1 activity could restore lysosomal function across multiple NDDs by promoting calcium-dependent lysosomal exocytosis and reformation.

Target: MCOLN1 (TRPML1 channel)

Supporting Evidence: TRPML1 mutations cause mucolipidosis IV with neurodegeneration (PMID: 12023275). TRPML1 activation rescues l

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

I'll provide a rigorous critique of each hypothesis, identifying key weaknesses and alternative explanations.

1. Lysosomal Calcium Channel Modulation Therapy (TRPML1)

Specific Weaknesses:

Selectivity issues: TRPML1 activation would affect all cell types, potentially causing off-target cardiac and smooth muscle effects given calcium's universal signaling role
Dose-response complexity: The evidence shows TRPML1 mutations cause disease, but this doesn't validate that enhancement is therapeutic - calcium homeostasis has narrow optimal ranges
Limited mechanistic depth

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Practical Feasibility Assessment

I'll evaluate each hypothesis through the lens of drug development reality, focusing on druggability, existing chemical matter, and commercial viability.

1. TRPML1 Channel Modulation - MODERATE FEASIBILITY

Druggability Assessment

Target Class: Ion channel - historically druggable but challenging for selectivity Chemical Matter:

ML-SA1 (synthetic agonist, Sigma-Aldrich): Proof-of-concept but poor selectivity, CNS penetration unknown
SN-2 (natural product derivative): Better selectivity but limited availability
**Curcumin analog

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

Price History

7d Trend

↔

Stable

7d Momentum

▼ 1.3%

Volatility

Medium

0.0342

Events (7d)

⚡ Price Movement Log Recent 15 events

	Event	Price	Change	Source	Time
📄	New Evidence	$0.518	▲ 1.8%	evidence_batch_update	2026-04-13 02:18
📄	New Evidence	$0.509	▲ 4.1%	evidence_batch_update	2026-04-13 02:18
⚖	Recalibrated	$0.489	▼ 0.3%		2026-04-12 10:15
⚖	Recalibrated	$0.490	▼ 1.1%		2026-04-10 15:58
⚖	Recalibrated	$0.495	▲ 1.3%		2026-04-10 15:53
⚖	Recalibrated	$0.489	▲ 0.3%		2026-04-08 18:39
⚖	Recalibrated	$0.487	▲ 2.3%		2026-04-06 04:04
⚖	Recalibrated	$0.476	▼ 0.6%		2026-04-04 16:38
⚖	Recalibrated	$0.479	▼ 2.2%		2026-04-04 16:02
📄	New Evidence	$0.490	▲ 2.7%	evidence_batch_update	2026-04-04 09:08
⚖	Recalibrated	$0.478	▼ 22.9%		2026-04-03 23:46
📄	New Evidence	$0.619	▲ 2.3%	evidence_batch_update	2026-04-03 01:06
📄	New Evidence	$0.605	▲ 2.8%	evidence_batch_update	2026-04-03 01:06
⚖	Recalibrated	$0.589	▲ 16.5%	market_dynamics	2026-04-03 01:06
⚖	Recalibrated	$0.505	▲ 8.2%		2026-04-02 21:55

Clinical Trials (4) Relevance: 9%

1
Active

3
Completed

0
Total Enrolled

Phase II
Highest Phase

Ambroxol for Parkinson's Disease (AIM-PD) Phase II

Completed · NCT02914366

Ambroxol in GBA-Parkinson's Disease Phase II

Recruiting · NCT04388969

Venglustat (GCS inhibitor) for GBA-Parkinson's Phase II

Completed · NCT02906020

DNL343 (eIF2B activator) in ALS Phase I

Completed · NCT04535050

📚 Cited Papers (44)

Designed endocytosis-inducing proteins degrade targets and amplify signals.

Nature (2025) · PMID:39322662

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

The mouse kinome: discovery and comparative genomics of all mouse protein kinases.

Proceedings of the National Academy of Sciences of the United States of America (2004) · PMID:15289607

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Interactions of IGF-II with the IGF2R/cation-independent mannose-6-phosphate receptor mechanism and biological outcomes.

Vitam Horm (2009) · PMID:19251056

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Protective immune responses against West Nile virus are primed by distinct complement activation pathways.

The Journal of experimental medicine (2006) · PMID:16651386

7 figures

Figure 1.

Complement is activated in vivo in response to WNV infection. Levels of functional (A) C3 and (B) C4 were determined by erythrocyte hemolysis assay of serum samples from naive and...

pmc_api

Figure 3.

WNV infection in serum and lymphoid tissues. WNV RNA levels in the serum (A), spleen (C), and draining inguinal lymph node (D) of wild-type, C1q −/− , C4 −/− , fD −/− , and fB −/−...

pmc_api

Revisiting LAMP1 as a marker for degradative autophagy-lysosomal organelles in the nervous system.

Autophagy (2018) · PMID:29940787

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

The mouse kinome: discovery and comparative genomics of all mouse protein kinases.

Proceedings of the National Academy of Sciences of the United States of America (2004) · PMID:15289607

No extracted figures yet

Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2.

Nature genetics (2005) · PMID:15654338

No extracted figures yet

Protective immune responses against West Nile virus are primed by distinct complement activation pathways.

The Journal of experimental medicine (2006) · PMID:16651386

No extracted figures yet

Interactions of IGF-II with the IGF2R/cation-independent mannose-6-phosphate receptor mechanism and biological outcomes.

Vitam Horm (2009) · PMID:19251056

No extracted figures yet

A novel rat model with obesity-associated retinal degeneration.

Investigative ophthalmology & visual science (2009) · PMID:19369235

No extracted figures yet

Hierarchical phosphorylation within the ankyrin repeat domain defines a phosphoregulatory loop that regulates Notch transcriptional activity.

The Journal of biological chemistry (2011) · PMID:21685388

No extracted figures yet

A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.

Journal of neurochemistry (2015) · PMID:25556849

No extracted figures yet

📙 Related Wiki Pages (15)

࢐ Browse all wiki pages

📓 Linked Notebooks (1)

📓 Autophagy-lysosome pathway convergence across neurodegenerative diseases — Analysis Notebook

CI-generated notebook stub for analysis sda-2026-04-01-gap-011. Multiple NDDs converge on autophagy-lysosome dysfunction. Are there universal therapeutic targets?

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score

0.76

50.5th percentile (747 hypotheses)

Tokens Used

9,425

KG Edges Generated

315

Citations Produced

Cost Ratios

Cost per KG Edge

70.86 tokens

Lower is better (baseline: 2000)

Cost per Citation

448.81 tokens

Lower is better (baseline: 1000)

Cost per Score Point

14726.56 tokens

Tokens / composite_score

Score Impact

Efficiency Boost to Composite

+0.076

10% weight of efficiency score

Adjusted Composite

0.781

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Efficiency Price Signals

Date	Signal Price	Score
2026-04-17T09:10	$0.644	0.546

Wiki Pages

KG Entities (51)

AKT APP ATG5 ATG7 Autophagy-lysosome pathway BECN1 C1Q C9ORF72 CHMP2B CHMP2B_protein ESCRT_III_pathway FOXO1 FOXO1_protein IGF2R LAMP1 LAMP2 LC3 Lysosomal function / degradation Lysosomal membrane / lysosomal function M6PR_protein

Dependency Graph (2 upstream, 0 downstream)

Depends On

Autophagosome Maturation Checkpoint Controlbuilds_on (0.6)Transcriptional Autophagy-Lysosome Couplingbuilds_on (0.6)

Linked Experiments (4)

Chaperone-Mediated Autophagy Dysfunction in PD - Experiment Designclinical | tests | 0.40 Proteasome-Ubiquitin System Dysfunction Validation in Parkinson's Diseaseclinical | tests | 0.40 Presymptomatic GRN Carrier Intervention Timing — Biomarker-Guided Therapy Initiaclinical | tests | 0.40 TMEM106B Haplotype as Genetic Modifier in FTD — Mechanism and Therapeutic Exploivalidation | tests | 0.40

Related Hypotheses

TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration

Score: 0.990 | neurodegeneration

TREM2-Dependent Microglial Senescence Transition

Score: 0.950 | neurodegeneration

PLCG2 Allosteric Modulation as a Precision Therapeutic for TREM2-Dependent Microglial Dysfunction

Score: 0.941 | neurodegeneration

Multi-Biomarker Composite Index Surpassing Amyloid PET for Treatment Response Prediction

Score: 0.933 | neurodegeneration

CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microglial Senescence Reversal

Score: 0.921 | neurodegeneration

Estimated Development

Estimated Cost

Timeline

22 months

🧪 Falsifiable Predictions (7)

7 total 0 confirmed 0 falsified

expect lysosomal dysfunction if enhancement is inherently harmful 2. Dose-escalation studies in NDD models - identify therapeutic window vs. toxicity threshold 3. Cell-type specific TRPML1 modulation to separate beneficial vs. detrimental effects

pending conf: 0.65